Since brain Rap1 activation has emerged as a causative factor for decreases in leptin responsiveness and obesity, the reduced activity of brain Rap1 signaling may coordinately contribute to the phenotypes of the oral YHIEPV treatment. This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.